In the EMPAG-HF (12), Tamaki (16), Pérez-Belmonte 2021 (19), and Nakagaito (11) trials, compared to the placebo, there were significantly larger decreases in mean NT-proBNP from baseline in the empagliflozin group compared to the control group. Here, NPPB is linked to hydrops fetalis.